Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) Research & Development (2016 - 2025)

vTv Therapeutics (VTVT) has disclosed Research & Development for 12 consecutive years, with $3.9 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 74.93% to $3.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.9 million through Dec 2025, up 54.69% year-over-year, with the annual reading at $17.9 million for FY2025, 54.69% up from the prior year.
  • Research & Development hit $3.9 million in Q4 2025 for vTv Therapeutics, down from $7.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $7.0 million in Q3 2025 to a low of $2.1 million in Q4 2023.
  • Historically, Research & Development has averaged $3.4 million across 5 years, with a median of $3.1 million in 2021.
  • Biggest five-year swings in Research & Development: crashed 46.06% in 2023 and later skyrocketed 117.74% in 2025.
  • Year by year, Research & Development stood at $5.4 million in 2021, then fell by 26.62% to $4.0 million in 2022, then plummeted by 46.06% to $2.1 million in 2023, then grew by 4.49% to $2.2 million in 2024, then surged by 74.93% to $3.9 million in 2025.
  • Business Quant data shows Research & Development for VTVT at $3.9 million in Q4 2025, $7.0 million in Q3 2025, and $4.1 million in Q2 2025.